| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 12/20/2001 | WO2001015693A3 Treatment of migraine by the administration of alpha-lipoic acid or derivatives thereof |
| 12/20/2001 | WO2001013949A3 Medical preparation for treating arthrosis, arthritis and other rheumatic joint diseases |
| 12/20/2001 | WO2001010426A3 Use of ep4 receptor ligands in the treatment of neuropathic pain and colon cancer |
| 12/20/2001 | WO2001002552A3 Double transgenic animals as models for neurodegenerative disease |
| 12/20/2001 | WO2000072834A9 Agent for expression of long-term potentiation of synaptic transmission comprising compound having brain somatostatin activation property |
| 12/20/2001 | WO1999063976A3 Liver-selective glucocorticoid antagonist for treating diabetes |
| 12/20/2001 | WO1999013923A3 Hydrogel wound dressing and the method of making and using the same |
| 12/20/2001 | US20010053853 Alkanoic acid derivative; integrin receptor antagonist |
| 12/20/2001 | US20010053844 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 12/20/2001 | US20010053798 S(+) desmethylselegiline and drug withdrawal |
| 12/20/2001 | US20010053795 Hypotensive agents |
| 12/20/2001 | US20010053793 Administering dehydroascorbic acid |
| 12/20/2001 | US20010053786 Methods for treating addictive disorders |
| 12/20/2001 | US20010053782 Pyrrolo[2,3-d]pyrimidine compounds |
| 12/20/2001 | US20010053778 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 12/20/2001 | US20010053777 Synergistic mixture containing alpha 2-antagonist agent and neuropsychic drug |
| 12/20/2001 | US20010053763 Method and composition for modulating an immune response |
| 12/20/2001 | US20010053761 Method for administering aspb28-human insulin |
| 12/20/2001 | US20010053760 Treatment of infarcts |
| 12/20/2001 | US20010053533 Detecting infectious protein in solution; prepare solution composed from body fluid or fluidized organ expose to chromatographic column, detect infectious protein |
| 12/20/2001 | US20010053370 Parkinson's disease treatment |
| 12/20/2001 | US20010053369 Treating a movement disorder by intracranial administration of a neurotoxin, especially a botulinium toxin |
| 12/20/2001 | US20010053361 Immunotherapy involving cd28 stimulation |
| 12/20/2001 | US20010053356 Garlic ingredients and antioxidants in the prevention and treatment of vascular-related disorders and pathological angiogenesis-mediated disorders |
| 12/20/2001 | US20010053351 Inhibition of GSK-3 beta |
| 12/20/2001 | US20010053347 Methods and compositions for preventing and treating chronological aging in human skin |
| 12/20/2001 | DE10026666A1 Verwendung von Hyaluronidase zur Prophylaxe und Behandlung von Herz-Kreislauf-Erkrankungen Use of hyaluronidase for the prophylaxis and treatment of cardiovascular diseases |
| 12/20/2001 | DE10024171A1 Neuronale Serin-Threonin-Protein-Kinase Neuronal serine threonine protein kinase |
| 12/20/2001 | CA2436116A1 Treatment and prevention of cardiac insulin resistance associated conditions |
| 12/20/2001 | CA2415369A1 Thromboxane receptor antagonist containing formulations for potentiating organic nitrates having vasodilating activity |
| 12/20/2001 | CA2412857A1 Hiv integrase inhibitors |
| 12/20/2001 | CA2412843A1 Composition comprising clinoptolite, plant extracts and vitamin b complex for diabetic neuropathy |
| 12/20/2001 | CA2412663A1 A human homologue of the dbf4/ask1 protein, nucleic acids, and methods related to the same |
| 12/20/2001 | CA2412632A1 Hmg-coa reductase inhibitors and method |
| 12/20/2001 | CA2412579A1 Methods to identify polynucleotide and polypeptide sequences which may be associated with physiological and medical conditions |
| 12/20/2001 | CA2412355A1 Method of treating symptoms of hormonal variation, including hot flashes, using tachykinin receptor antagonist |
| 12/20/2001 | CA2412165A1 Liposomal benzoquinazoline thymidylate synthase inhibitor formulations |
| 12/20/2001 | CA2411962A1 Methods for regulating a cell-mediated immune response by blockinglymphocytic signals and by blocking lfa-1 mediated adhesion |
| 12/20/2001 | CA2411813A1 Tricyclic compounds as mrp1-inhibitors |
| 12/20/2001 | CA2411401A1 Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids |
| 12/20/2001 | CA2411278A1 Compositions and methods for the therapy and diagnosis of colon cancer |
| 12/20/2001 | CA2410659A1 Transgenic mice containing nuclear hormone receptor gene disruptions |
| 12/20/2001 | CA2410610A1 Human kinases |
| 12/20/2001 | CA2410228A1 A combination product comprising melagatran and a factor viia inhibitor |
| 12/20/2001 | CA2410100A1 A combination product comprising melagatran and a factor xa inhibitor |
| 12/20/2001 | CA2409315A1 Protein phosphatases |
| 12/20/2001 | CA2408575A1 Cosmetic and/or dermatological composition based on cocoa extracts |
| 12/20/2001 | CA2407699A1 Use of an aldosterone antagonist for the treatment or prophylaxis of aldosterone-mediated pathogenic effects |
| 12/19/2001 | EP1163528A2 Prediction of diabetes impaired wound healing |
| 12/19/2001 | EP1163524A2 Methods of screening for colorectal cancer modulators |
| 12/19/2001 | EP1163523A1 Method for detecting predisposition to a venous thromboembolic disease |
| 12/19/2001 | EP1163522A1 Method for detecting superantigen activity in a biological sample |
| 12/19/2001 | EP1163515A1 Therapeutic and diagnostic tools for impaired glucose tolerance conditions |
| 12/19/2001 | EP1163364A1 Screening method involving mgdg synthase |
| 12/19/2001 | EP1163345A1 Fungal beta-tubulin genes |
| 12/19/2001 | EP1163331A1 50 human secreted proteins |
| 12/19/2001 | EP1163272A1 Antibodies specific for cyp1b1 |
| 12/19/2001 | EP1163270A1 Dihydroouabain-like factor and diagnostic and therapeutic compositions and methods |
| 12/19/2001 | EP1163254A2 Trpm-2 antisense therapy |
| 12/19/2001 | EP1163252A2 Compositions, kits, and methods relating to the human fez1 gene, a novel tumor suppressor gene |
| 12/19/2001 | EP1163243A2 Calanolides for inhibiting btk |
| 12/19/2001 | EP1163238A1 Chemokine recpetor binding heterocyclic compounds |
| 12/19/2001 | EP1163209A1 Compounds and compositions for delivering active agents |
| 12/19/2001 | EP1163019A1 Medical devices and applications of polyhydroxyalkanoate polymers |
| 12/19/2001 | EP1163011A2 Fatty acid-anticancer conjugates and uses thereof |
| 12/19/2001 | EP1163009A1 Gel-microemulsion formulations |
| 12/19/2001 | EP1163003A1 Treatment of lfa-1 associated disorders with increasing doses of lfa-1 antagonist |
| 12/19/2001 | EP1163002A2 Polycationic carbohydrates as immunostimulants in vaccines |
| 12/19/2001 | EP1163001A2 Vaccine composition |
| 12/19/2001 | EP1162984A2 Use of cross linked polysaccharides for the inhibition of angiogenesis |
| 12/19/2001 | EP1162981A1 Treatment of accidental extravasation of anthracyclines |
| 12/19/2001 | EP1162970A2 Anti-inflammatory uses of manzamines |
| 12/19/2001 | EP1162969A2 Compositions for improving fertility |
| 12/19/2001 | EP1162968A1 Use of epigallocatechin-gallate for inhibiting angiogenesis |
| 12/19/2001 | EP1162967A1 The use of certain affinity nmda antagonists as antidepressants |
| 12/19/2001 | EP1162960A2 Pharmaceutical compositions for the treatment of posttraumatic stress disorder |
| 12/19/2001 | EP1162945A1 Particle based vaccine composition |
| 12/19/2001 | EP1162937A1 Compositions based on chondroitin sulphate and chitosan for preventing or treating rheumatic disorders by general administration |
| 12/19/2001 | EP1162915A1 Electromagnetic object detector provided with an additional electrode and intended for a medical radiation apparatus |
| 12/19/2001 | EP1162884A1 Oral low dose butyrate compositions |
| 12/19/2001 | EP1014965A4 Dietary compositions for enhancing metabolism and alleviating oxidative stress |
| 12/19/2001 | EP0979093B1 Arrestable therapeutic viral agent |
| 12/19/2001 | EP0683665B1 Magnetically responsive composition for carrying biologically active substances and methods of production and use |
| 12/19/2001 | EP0535021B1 Association between a human immunodeficiency virus-related retrovirus and sjogren's syndrome |
| 12/19/2001 | EP0493485B1 Erection-inducing methods and compositions |
| 12/19/2001 | EP0437488B2 Animal model for human disease |
| 12/19/2001 | CN1326786A Anti-cancer medicine composition |
| 12/19/2001 | CN1326785A Anti-cancer medicine composition |
| 12/19/2001 | CN1326743A Process for preparing 1,3-oxygen-sulphur cyclopentane nucleotide like medicine composition |
| 12/19/2001 | CN1076196C Pharmaceutical composition |
| 12/19/2001 | CA2350857A1 The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
| 12/18/2001 | US6331613 Nucleotide sequences coding protein associated with cytokine activity; for use in treating allergies, autoimmune diseases and acquired immune deficiency syndrome; for preventing cell differentiation; for activating tissue regeneration |
| 12/18/2001 | US6331571 Methods of treating and preventing attention deficit disorders |
| 12/18/2001 | US6331539 Sulfonamide and sulfamide substituted imidazoquinolines |
| 12/18/2001 | US6331536 Administering to patient in need thereof effective amount of serotonin receptor antagonist to prevent or ameliorate sleep-related breathing disorder |
| 12/18/2001 | US6331528 Expressing thymidine kinase gene in cell and administering9-(1*,2*-bis(hydroxymethyl)cyclopropan-1*-yl)meth ylguanine |
| 12/18/2001 | US6331525 Targeted delivery of genes encoding interferon |
| 12/18/2001 | US6331423 Nucleotide sequences coding polypeptide for use as human therapeutic agents that modulate kinase activity |
| 12/18/2001 | US6331411 TopA |
| 12/18/2001 | US6331313 Controlled-release biocompatible ocular drug delivery implant devices and methods |